U.S. jury finds Takeda liable for antitrust scheme to delay generic drug

🤖AI Özeti

A U.S. jury has ruled that Takeda Pharmaceutical Company engaged in an antitrust scheme to delay the entry of a generic constipation drug into the market. This landmark verdict marks the first instance where a jury has held a pharmaceutical firm accountable in class-action litigation concerning a 'pay-for-delay' agreement with generic competitors. The ruling could have significant implications for the pharmaceutical industry and its practices regarding generic drug competition.